YOLFTbeta
Biophytis S.A.

Biophytis S.A.

ALBPS · PA · Healthcare / Biotechnology

0.0373EUR-0.00 (-5.09%)

Price History

Full chart

Market Stats

Previous Close0.0393
Open0.039
Day Range0.0371 – 0.0406
52-Week Range0.0042 – 0.183
Volume14.94M
Market Cap21.63M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.34
Dividend Yield0.00%
Beta1.65
50-Day Avg0.0562
200-Day Avg0.0388

About

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Stanislas Veillet Ph.D.
  • Employees19
  • Headquarters14 avenue de l'Opéra, Paris, France, 75001, France
  • Websitehttps://www.biophytis.com

Leadership

  • Mr. Stanislas Veillet Ph.D.Chairman of the Board & CEO · b. 1965
  • Mr. Christophe CourtillatChief Financial Officer
  • Mr. Waly Dioh Ph.D.Chief Operating Officer · b. 1969
  • Dr. Pierre J. Dilda Ph.D.Chief Scientific Officer · b. 1970
  • Dr. Rene LafontScientific Advisor & Member of Scientific Advisory Board · b. 1946
  • Mr. Edouard BiethChief Strategy Officer · b. 1981
  • Ms. . TeylanFinancial Controller

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Revenue000000000000
Cost of Revenue0065.00K167.00K204.00K227.00K262.00K280.00K311.00K484.00K803.00K298.00K
Gross Profit00-65.00K-167.00K-204.00K-227.00K-262.00K-280.00K-311.00K-484.00K-803.00K-298.00K
Operating Expense498.33K673.98K3.03M7.78M9.70M13.63M15.42M13.66M26.50M22.79M13.53M8.20M
Operating Income-498.33K-673.98K-3.10M-7.94M-9.91M-13.86M-15.68M-13.94M-26.82M-23.27M-14.33M-8.50M
EBITDA-467.99K-704.63K-4.98M-7.78M-9.81M-13.63M-15.42M-13.66M-26.50M-25.52M-13.80M-8.26M
Net Income-521.55K-708.94K-5.23M-7.95M-11.41M-13.99M-18.95M-25.52M-33.53M-24.22M-17.03M-10.38M
R&D689.52K725.63K1.57M5.12M7.04M9.51M9.09M9.92M19.66M16.03M10.41M4.47M
Interest Expense00172.50K35.00K3.29M185.00K2.53M4.37M4.43M1.60M1.25M872.00K

Balance Sheet

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Total Assets1.21M627.76K386.86K13.52M8.39M25.95M21.86M17.67M27.21M36.26M21.99M11.96M6.90M
Total Liabilities1.08M1.04M1.52M1.85M3.87M4.76M14.86M25.20M20.38M30.56M23.90M15.85M16.60M
Total Equity151.88K-380.20K-1.10M11.70M4.55M21.22M7.04M-7.54M2.30M5.83M-1.88M-3.86M-9.67M
Cash623.38K43.00K9.36K9.41M3.07M19.86M14.41M6.34M5.85M23.93M11.05M5.57M78.00K
Total Debt580.47K463.23K724.67K802.79K1.09M1.01M8.20M15.24M9.10M17.55M14.58M8.27M9.84M
Net Debt-42.91K420.23K715.31K-8.61M-1.98M-18.84M-6.21M8.91M3.25M-8.55M1.07M2.70M9.76M

Cash Flow

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow-803.29K-658.89K-3.21M-6.63M-8.73M-12.06M-15.27M-9.86M-23.80M-18.99M-12.87M-8.64M
Investing Cash Flow-3.77K-2.66K-6.19K-129.00K-128.00K-104.00K-278.00K-12.71M12.16M-17.00K370.00K10.00K
Financing Cash Flow232.47K615.77K12.63M407.00K25.65M6.77M7.50M21.95M29.71M6.13M7.03M3.14M
Capital Expenditure3.77K2.66K6.19K129.00K128.00K113.00K282.00K214.00K344.00K141.00K220.00K9.15M
Free Cash Flow-807.07K-661.54K-3.22M-6.76M-8.86M-12.17M-15.55M-10.08M-24.14M-19.13M-13.09M-8.64M
Dividends Paid----0000000-
FCF to OCF100.47%100.40%100.19%101.94%101.47%100.94%101.85%102.17%101.45%100.74%101.71%100.00%
Dividend Paid to FCF----0.00%0.00%0.00%0.00%0.00%0.00%0.00%-

Earnings

Report DateFeb 3, 2016Sep 29, 2016Jul 31, 2017Oct 26, 2017Mar 28, 2018May 30, 2018Oct 22, 2018Mar 11, 2019Jun 23, 2019Aug 28, 2019Oct 31, 2019Mar 17, 2020Apr 5, 2020Oct 26, 2020Feb 26, 2021May 20, 2021Sep 17, 2021Dec 1, 2021Feb 26, 2022May 26, 2022Oct 31, 2022Feb 27, 2023Apr 18, 2023Jul 21, 2023Oct 23, 2023Feb 26, 2024Apr 8, 2024Sep 30, 2024Nov 27, 2024Mar 31, 2025May 30, 2025Sep 29, 2025Oct 31, 2025Feb 23, 2026
EPS Estimate0.000.000.000.00-92.00-0.28-0.28-104.00-112.00-104.00-0.25-0.25-100.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.95-0.200.00-0.280.00-0.280.000.00
EPS Actual-0.59-0.60-0.68-0.81-72.00-112.00-0.28-76.00-72.00-0.760.00-0.37-76.00-0.25-0.280.00-0.140.00-0.140.00-0.080.00-0.060.000.000.00-1.05-0.200.00-1.660.00-0.66-0.180.00
Surprise----21.74%-39900.00%0.00%26.92%35.71%99.27%100.00%-48.00%24.00%--------------10.53%0.20%--500.80%--138.87%--
Timing--Pre-marketPre-marketPre-market-After-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hours-Pre-market-Pre-market--After-hoursAfter-hours-Pre-marketPre-marketAfter-hours------Pre-market--

Key Statistics & Ratios

Market Cap21.63M
Enterprise Value29.95M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.96
EPS-0.34
Book Value-0.333
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-7.87M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1244.40%
Return on Assets-66.56%
Shares Outstanding477.54M
Shares Float23.36M
Beta1.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 3, 20241:400